Inflammation and prostate cancer: friends or foe?

详细信息    查看全文

• 作者：Gianluigi Taverna (1)
  Elisa Pedretti (2)
  Giuseppe Di Caro (2)
  Elena Monica Borroni (3)
  Federica Marchesi (2)
  Fabio Grizzi (2)
  
  1. Department of Urology ; Humanitas Clinical and Research Center ; Rozzano ; Milan ; Italy
  2. Department of Immunology and Inflammation ; Humanitas Clinical and Research Center ; Via Manzoni 56 ; 20089 ; Rozzano ; Milan ; Italy
  3. Department of Biotechnology and Translational Medicine ; University of Milan ; Milan ; Italy
  
• 关键词：Prostate ; Cancer ; Immunity ; Chemokines
• 刊名：Inflammation Research
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：64
• 期：5
• 页码：275-286
• 全文大小：840 KB
• 参考文献：1. Shukla, ME, Yu, C, Reddy, CA, Stephans, KL, Klein, EA, Abdel-Wahab, M (2015) Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database. Clinical Genitourin Cancer 13: pp. 17-21
  2. Siegel, R, Ma, J, Zou, Z, Jemal, A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: pp. 9-29
  3. Loeb, S, Catalona, WJ (2007) Prostate-specific antigen in clinical practice. Cancer Lett 249: pp. 30-39
  4. Loeb, S, Gashti, SN, Catalona, WJ (2009) Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Urol Oncol 27: pp. 64-66
  5. Schroder, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Ciatto, S, Nelen, V (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: pp. 1320-1328
  6. Presti, JC (2007) Prostate biopsy strategies. Nat Clin Prac Urol 4: pp. 505-511
  7. Taverna, G, Maffezzini, M, Benetti, A, Seveso, M, Giusti, G, Graziotti, P (2002) A single injection of lidocaine as local anesthesia for ultrasound guided needle biopsy of the prostate. J Urol 167: pp. 222-223
  8. Scattoni, V, Maccagnano, C, Capitanio, U, Gallina, A, Briganti, A, Montorsi, F (2014) Random biopsy: when, how many and where to take the cores?. World J Urol 32: pp. 859-869
  9. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol/Int Acad Cytol Am Soc Cytol. 2008;30(4):190鈥?. (PubMed PMID: 18773736).
  10. Rubin, MA (2008) Targeted therapy of cancer: new roles for pathologists鈥損rostate cancer. Modern Pathol: Off J US Can Acad Pathol, Inc. 21: pp. S44-S55
  11. McDunn, JE, Li, Z, Adam, KP, Neri, BP, Wolfert, RL, Milburn, MV (2013) Metabolomic signatures of aggressive prostate cancer. Prostate 73: pp. 1547-1560
  12. Schmid, M, Hansen, J, Rink, M, Fisch, M, Chun, F (2013) The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. Biomark Med 7: pp. 843-850
  13. Dimakakos, A, Armakolas, A, Koutsilieris, M (2014) Novel tools for prostate cancer prognosis, diagnosis, and follow-up. BioMed Res Int. 2014: pp. 890697
  14. Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2014;0 (PubMed PMID: 24837368).
  15. Qu, M, Ren, SC, Sun, YH (2014) Current early diagnostic biomarkers of prostate cancer. Asian J Androl. 16: pp. 549-554
  16. Klotz, L (2013) Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 20: pp. 204-209
  17. Veeranki, S (2013) Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cell Mol Biol Lett 18: pp. 355-367
  18. Orsted, DD, Bojesen, SE (2013) The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 10: pp. 49-54
  19. Nakai, Y, Nonomura, N (2013) Inflammation and prostate carcinogenesis. Int J Urol: Off J Jpn Urol Assoc 20: pp. 150-160
  20. Taverna, G, Seveso, M, Giusti, G, Hurle, R, Graziotti, P, Stifter, S (2014) Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res. 2014: pp. 478126
  21. De Marzo, AM, Platz, EA, Sutcliffe, S, Xu, J, Gronberg, H, Drake, CG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7: pp. 256-269
  22. Ittmann, M, Huang, J, Radaelli, E, Martin, P, Signoretti, S, Sullivan, R (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 73: pp. 2718-2736
  23. Montironi, R, Lopez-Beltran, A, Mazzucchelli, R, Scarpelli, M, Galosi, AB, Cheng, L (2014) Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol/Int Acad Cytol Am Soc Cytol. 36: pp. 61-70
  24. Ammirante, M, Luo, JL, Grivennikov, S, Nedospasov, S, Karin, M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 464: pp. 302-305
  25. Gurel B, Lucia MS, Thompson IM, Jr., Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(5):847鈥?6. (PubMed PMID: 24748218. Pubmed Central PMCID: 4012292).
  26. Klinke, DJ (2012) An evolutionary perspective on anti-tumor immunity. Front Oncol. 2: pp. 202
  27. Chiarugi, P, Paoli, P, Cirri, P (2014) Tumor microenvironment and metabolism in prostate cancer. Semin Oncol 41: pp. 267-280
  28. Goldstein, AS, Witte, ON (2013) Does the microenvironment influence the cell types of origin for prostate cancer?. Genes Dev 27: pp. 1539-1544
  29. Sfanos, KS, Hempel, HA, Marzo, AM (2014) The role of inflammation in prostate cancer. Adv Exp Med Biol 816: pp. 153-181
  30. Vykhovanets EV, Maclennan GT, Vykhovanets OV, Gupta S. IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. Int J Clin Exp Pathol. 2011;4(6):552鈥?5. (PubMed PMID: 21904631. Pubmed Central PMCID: 3160607. Epub 2011/09/10. eng).
  31. Fang, LY, Izumi, K, Lai, KP, Liang, L, Li, L, Miyamoto, H (2013) Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res 73: pp. 5633-5646
  32. Okada, K, Kojima, M, Naya, Y, Kamoi, K, Yokoyama, K, Takamatsu, T (2000) Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 55: pp. 892-898
  33. Pittoni, P, Colombo, MP (2012) The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 72: pp. 831-835
  34. Taverna, G, Giusti, G, Seveso, M, Hurle, R, Colombo, P, Stifter, S (2013) Mast cells as a potential prognostic marker in prostate cancer. Dis Markers. 35: pp. 711-720
  35. Globa, T, Saptefrti, L, Ceausu, RA, Gaje, P, Cimpean, AM, Raica, M (2014) Mast cell phenotype in benign and malignant tumors of the prostate. Pol J Pathol: Off J Pol Soc Pathol 65: pp. 147-153
  36. Frankel, TL, Burns, W, Riley, J, Morgan, RA, Davis, JL, Hanada, K (2010) Identification and characterization of a tumor infiltrating CD56(+)/CD16(鈭? NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunol Immunother. 59: pp. 1757-1769
  37. Kryvenko, ON, Jankowski, M, Chitale, DA, Tang, D, Rundle, A, Trudeau, S (2012) Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol: Off J US Can Acad Pathol, Inc. 25: pp. 1023-1032
  38. Sfanos, KS, Marzo, AM (2012) Prostate cancer and inflammation: the evidence. Histopathology. 60: pp. 199-215
  39. Flammiger, A, Bayer, F, Cirugeda-Kuhnert, A, Huland, H, Tennstedt, P, Simon, R (2012) Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. Apmis. 120: pp. 901-908
  40. McDowell, KL, Begley, LA, Mor-Vaknin, N, Markovitz, DM, Macoska, JA (2010) Leukocytic promotion of prostate cellular proliferation. Prostate. 70: pp. 377-389
  41. Liu, Y, Saeter, T, Vlatkovic, L, Servoll, E, Waaler, G, Axcrona, U (2013) Dendritic and lymphocytic cell infiltration in prostate carcinoma. Histol Histopathol 28: pp. 1621-1628
  42. Hussein, MR, Al-Assiri, M, Musalam, AO (2009) Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 86: pp. 108-113
  43. Nunzio, C, Kramer, G, Marberger, M, Montironi, R, Nelson, W, Schroder, F (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60: pp. 106-117
  44. Lakshmi Narendra, B, Eshvendar Reddy, K, Shantikumar, S, Ramakrishna, S (2013) Immune system: a double-edged sword in cancer. Inflamm Res: Off J Eur Hist Res Soc [et al] 62: pp. 823-834
  45. Mantovani, A, Allavena, P, Sica, A, Balkwill, F (2008) Cancer-related inflammation. Nature 454: pp. 436-444
  46. Coussens, LM, Werb, Z (2002) Inflammation and cancer. Nature. 420: pp. 860-867
  47. Biswas, SK, Mantovani, A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: pp. 889-896
  48. Mantovani, A, Sica, A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: pp. 231-237
  49. Sica, A, Larghi, P, Mancino, A, Rubino, L, Porta, C, Totaro, MG (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18: pp. 349-355
  50. Lanciotti, M, Masieri, L, Raspollini, MR, Minervini, A, Mari, A, Comito, G (2014) The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed Res Int. 2014: pp. 486798
  51. Marzo, AM, Marchi, VL, Epstein, JI, Nelson, WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 155: pp. 1985-1992
  52. Comito, G, Giannoni, E, Segura, CP, Barcellos-de-Souza, P, Raspollini, MR, Baroni, G (2014) Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 33: pp. 2423-2431
  53. Xu, J, Escamilla, J, Mok, S, David, J, Priceman, S, West, B (2013) CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 73: pp. 2782-2794
  54. Fujii, T, Shimada, K, Asai, O, Tanaka, N, Fujimoto, K, Hirao, K (2013) Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiol: J Immunopathol Mol Cell Biol. 80: pp. 119-126
  55. Kakehi, Y, Segawa, T, Wu, XX, Kulkarni, P, Dhir, R, Getzenberg, RH (2004) Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate 59: pp. 351-356
  56. Dubey, S, Vanveldhuizen, P, Holzbeierlein, J, Tawfik, O, Thrasher, JB, Karan, D (2012) Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncol Lett. 3: pp. 1166-1170
  57. Pickup, M, Novitskiy, S, Moses, HL (2013) The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 13: pp. 788-799
  58. Vanhara, P, Hampl, A, Kozubik, A, Soucek, K (2012) Growth/differentiation factor-15: prostate cancer suppressor or promoter?. Prostate Cancer Prostatic Dis. 15: pp. 320-328
  59. Wang, T, Welte, T (2013) Role of natural killer and Gamma-delta T cells in West Nile virus infection. Viruses. 5: pp. 2298-2310
  60. Yuan, H, Hsiao, YH, Zhang, Y, Wang, J, Yin, C, Shen, R (2013) Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer. 13: pp. 258
  61. Jaillon, S, Galdiero, MR, Prete, D, Cassatella, MA, Garlanda, C, Mantovani, A (2013) Neutrophils in innate and adaptive immunity. Semin Immunopathol. 35: pp. 377-394
  62. Fujita, K, Imamura, R, Tanigawa, G, Nakagawa, M, Hayashi, T, Kishimoto, N (2012) Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis 15: pp. 386-390
  63. Bekes, EM, Schweighofer, B, Kupriyanova, TA, Zajac, E, Ardi, VC, Quigley, JP (2011) Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 179: pp. 1455-1470
  64. Keizman, D, Gottfried, M, Ish-Shalom, M, Maimon, N, Peer, A, Neumann, A (2012) Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 17: pp. 1508-1514
  65. Raval, RR, Sharabi, AB, Walker, AJ, Drake, CG, Sharma, P (2014) Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2: pp. 14
  66. McArdle, PA, Canna, K, McMillan, DC, McNicol, AM, Campbell, R, Underwood, MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 91: pp. 541-543
  67. Yuan, H, Wei, X, Zhang, G, Li, C, Zhang, X, Hou, J (2011) B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 186: pp. 1093-1099
  68. Si, TG, Wang, JP, Guo, Z (2013) Analysis of circulating regulatory T cells (CD4+聽CD25+聽CD127鈭? after cryosurgery in prostate cancer. Asian J Androl. 15: pp. 461-465
  69. Miller, AM, Lundberg, K, Ozenci, V, Banham, AH, Hellstrom, M, Egevad, L (2006) CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 177: pp. 7398-7405
  70. Yokokawa, J, Cereda, V, Remondo, C, Gulley, JL, Arlen, PM, Schlom, J (2008) Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 14: pp. 1032-1040
  71. Sfanos, KS, Bruno, TC, Maris, CH, Xu, L, Thoburn, CJ, DeMarzo, AM (2008) Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clinical Cancer Research: Off J Am Assoc Cancer Res. 14: pp. 3254-3261
  72. Zou, L, Barnett, B, Safah, H, Larussa, VF, Evdemon-Hogan, M, Mottram, P (2004) Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64: pp. 8451-8455
  73. Davidsson, S, Ohlson, AL, Andersson, SO, Fall, K, Meisner, A, Fiorentino, M (2013) CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Modern Pathol: Off J US Can Acad Pathol, Inc. 26: pp. 448-455
  74. Gannon, PO, Alam Fahmy, M, Begin, LR, Djoukhadjian, A, Filali-Mouhim, A, Lapointe, R (2006) Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 66: pp. 1710-1720
  75. Vindrieux, D, Escobar, P, Lazennec, G (2009) Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16: pp. 663-673
  76. Balkwill, FR (2012) The chemokine system and cancer. J Pathol 226: pp. 148-157
  77. Vendramini-Costa, DB, Carvalho, JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18: pp. 3831-3852
  78. Salazar, N, Castellan, M, Shirodkar, SS, Lokeshwar, BL (2013) Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Critical Rev Eukaryot Gene Expr. 23: pp. 77-91
  79. Gajewski, TF, Schreiber, H, Fu, YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14: pp. 1014-1022
  80. Bonecchi, R, Galliera, E, Borroni, EM, Corsi, MM, Locati, M, Mantovani, A (2009) Chemokines and chemokine receptors: an overview. Front Biosci. 14: pp. 540-551
  81. Mantovani, A, Savino, B, Locati, M, Zammataro, L, Allavena, P, Bonecchi, R (2010) The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21: pp. 27-39
  82. Chow, MT, Luster, AD (2014) Chemokines in cancer. Cancer Immunol Res. 2: pp. 1125-1131
  83. Allavena, P, Germano, G, Marchesi, F, Mantovani, A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317: pp. 664-673
  84. Koizumi, K, Hojo, S, Akashi, T, Yasumoto, K, Saiki, I (2007) Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: pp. 1652-1658
  85. Ben-Baruch, A (2008) Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25: pp. 345-356
  86. Zlotnik, A, Burkhardt, AM, Homey, B (2011) Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 11: pp. 597-606
  87. Wu, Q, Dhir, R, Wells, A (2012) Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 11: pp. 3
  88. Gillies, K, Wertman, J, Charette, N, Dupre, DJ (2013) Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line. Cell Physiol Biochem: Int J Exper Cell Physiol Biochem Pharmacol 32: pp. 74-85
  89. Kato, T, Fujita, Y, Nakane, K, Mizutani, K, Terazawa, R, Ehara, H (2013) CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine 64: pp. 251-257
  90. Zhu, F, Liu, P, Li, J, Zhang, Y (2014) Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression. Oncol Rep 31: pp. 2049-2054
  91. Lam, C, Pavel, MA, Kashyap, P, Salehi-Najafabadi, Z, Valentino, V, Yu, Y (2014) Detection of CXCR2 cytokine receptor surface expression using immunofluorescence. Methods Mol Biol 1172: pp. 193-200
  92. Peng, C, Zhou, K, An, S, Yang, J (2015) The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med. 36: pp. 329-335
  93. Maxwell, PJ, Neisen, J, Messenger, J, Waugh, DJ (2014) Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 5: pp. 4895-4908
  94. Culig, Z (2013) CXCL8, an underestimated 鈥渂ad guy鈥?in prostate cancer. Eur Urol. 64: pp. 189-190
  95. Benelli, R, Stigliani, S, Minghelli, S, Carlone, S, Ferrari, N (2013) Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate 73: pp. 941-951
  96. Lin, TH, Liu, HH, Tsai, TH, Chen, CC, Hsieh, TF, Lee, SS (2013) CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta 1830: pp. 4917-4927
  97. Fang, LY, Izumi, K, Lai, KP, Liang, L, Li, L, Miyamoto, H (2013) Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer research. 73: pp. 5633-5646
  98. Ammirante, M, Shalapour, S, Kang, Y, Jamieson, CA, Karin, M (2014) Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci USA 111: pp. 14776-14781
  99. Chen, G, Liang, YX, Zhu, JG, Fu, X, Chen, YF, Mo, RJ (2014) CC chemokine ligand 18 correlates with malignant progression of prostate cancer. BioMed Res Int. 2014: pp. 230183
  100. Singh, RK, Lokeshwar, BL (2011) The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71: pp. 3268-3277
  101. Ellem, SJ, Taylor, RA, Furic, L, Larsson, O, Frydenberg, M, Pook, D (2014) A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. J Pathol 234: pp. 86-98
  102. Lin, WJ, Izumi, K (2014) Androgen receptor, ccl2, and epithelial-mesenchymal transition: A dangerous affair in the tumor microenvironment. Oncoimmunology. 3: pp. e27871
  103. Izumi, K, Fang, LY, Mizokami, A, Namiki, M, Li, L, Lin, WJ (2013) Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med. 5: pp. 1383-1401
  104. Bao, BY, Yao, J, Lee, YF (2006) 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27: pp. 1883-1893
  105. Velonas, VM, Woo, HH, Remedios, CG, Assinder, SJ (2013) Current status of biomarkers for prostate cancer. Int J Mol Sci. 14: pp. 11034-11060
  106. Balk, SP, Ko, YJ, Bubley, GJ (2003) Biology of prostate-specific antigen. J Clin Oncol 21: pp. 383-391
  107. Makarov, DV, Loeb, S, Getzenberg, RH, Partin, AW (2009) Biomarkers for prostate cancer. Annu Rev Med 60: pp. 139-151
  108. Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, et al. CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat: Off J Korean Cancer Assoc. 2014. doi:10.4143/crt.2014.015 (PubMed PMID: 25483747).
  109. Xu, Y, Zhang, L, Sun, SK, Zhang, X (2014) CC chemokine ligand 18 and IGF-binding protein 6 as potential serum biomarkers for prostate cancer. Tohoku J Exper Med 233: pp. 25-31
  110. Sharma, J, Gray, KP, Harshman, LC, Evan, C, Nakabayashi, M, Fichorova, R (2014) Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 74: pp. 820-828
  111. Agarwal, M, He, C, Siddiqui, J, Wei, JT, Macoska, JA (2013) CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 73: pp. 573-581
  112. Miyake, M, Lawton, A, Goodison, S, Urquidi, V, Rosser, CJ (2014) Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathol Res Pract 210: pp. 74-78
  113. Bostwick, DG, Burke, HB, Djakiew, D, Euling, S, Ho, SM, Landolph, J (2004) Human prostate cancer risk factors. Cancer 101: pp. 2371-2490
  114. Wallace, TA, Prueitt, RL, Yi, M, Howe, TM, Gillespie, JW, Yfantis, HG (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68: pp. 927-936
  115. Isman, FK, Kucukgergin, C, Dasdemir, S, Cakmakoglu, B, Sanli, O, Seckin, S (2012) Association between SDF1-3鈥睞 or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases. Mol Biol Rep 39: pp. 11073-11079
  116. Mandal, RK, Agrawal, T, Mittal, RD (2015) Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer. Tumour Biol: J Int Soc Oncodevelopment Biol Med. 36: pp. 375-381
  117. Kirk, PS, Koreckij, T, Nguyen, HM, Brown, LG, Snyder, LA, Vessella, RL (2013) Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Int J Mol Sci. 14: pp. 10483-10496
  118. Zhang, J, Patel, L, Pienta, KJ (2010) Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci. 95: pp. 31-53
  119. Zhang, J, Lu, Y, Pienta, KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 102: pp. 522-528
  120. Arnatt, CK, Adams, JL, Zhang, Z, Haney, KM, Li, G, Zhang, Y (2014) Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Bioorg Med Chem Lett 24: pp. 2319-2323
  121. Arnatt, CK, Zaidi, SA, Zhang, Z, Li, G, Richardson, AC, Ware, JL (2013) Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Eur J Med Chem 69: pp. 647-658
  122. Bhardwaj, A, Srivastava, SK, Singh, S, Arora, S, Tyagi, N, Andrews, J (2014) CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 5: pp. 11490-11500
  123. Domanska, UM, Timmer-Bosscha, H, Nagengast, WB, Oude Munnink, TH, Kruizinga, RC, Ananias, HJ (2012) CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia. 14: pp. 709-718
  124. Rhee, YH, Chung, PS, Kim, SH, Ahn, JC (2014) CXCR4 and PTEN are involved in the anti-metastatic regulation of anethole in DU145 prostate cancer cells. Biochem Biophys Res Commun. 447: pp. 557-562
  125. Mackinnon, AC, Yan, BC, Joseph, LJ, Al-Ahmadie, HA (2009) Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 133: pp. 1033-1040
  126. Gerlinger, M, Catto, JW, Orntoft, TF, Real, FX, Zwarthoff, EC, Swanton, C (2015) Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol 67: pp. 729-737
  127. Demichelis, F, Stanford, JL (2015) Genetic predisposition to prostate cancer: Update and future perspectives. Urol Oncol 33: pp. 75-84
  128. Franco, OE, Hayward, SW (2012) Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol. 65: pp. 267-313
  129. Iacopino, F, Angelucci, C, Sica, G (2012) Interactions between normal human fibroblasts and human prostate cancer cells in a co-culture system. Anticancer Res. 32: pp. 1579-1588
  130. Parrinello, S, Coppe, JP, Krtolica, A, Campisi, J (2005) Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 118: pp. 485-496
  131. Gharaee-Kermani, M, Kasina, S, Moore, BB, Thomas, D, Mehra, R, Macoska, JA (2012) CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PloS one. 7: pp. e49278
  132. Mimeault, M, Batra, SK (2013) Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World J Clin Oncol. 4: pp. 4-13
  133. Gutkin, DW, Shurin, MR (2014) Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother 63: pp. 45-57
  134. Fridman, WH, Pages, F, Sautes-Fridman, C, Galon, J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: pp. 298-306
  135. Vignozzi, L, Maggi, M (2014) Prostate cancer: intriguing data on inflammation and prostate cancer. Nat Rev Urol. 11: pp. 369-370
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Immunology
  Pharmacology and Toxicology
  Allergology
  Dermatology
  Neurology
  Rheumatology
  
• 出版者：Birkh盲user Basel
• ISSN：1420-908X

文摘

Introduction Prostate cancer is the most common non-cutaneous malignancy diagnosed in men. Moving from histological observations since a long time, it has been recognized that innate and adaptive immunity actively participates in the pathogenesis, surveillance, and progression of prostate cancer. Materials and methods A PubMed and Web of Science databases search was performed for studies providing evidence on the roles of the innate and adaptive immunity during the development and progression of prostate cancer. Conclusions There are growing evidences that chronic inflammation is involved in the regulation of cellular events in prostate carcinogenesis, including disruption of the immune response and regulation of the tumor microenvironment. This review discusses the role played by the innate and adaptive immune system in the local progression of prostate cancer, and the prognostic information that we can currently understand and exploit.